12

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Dynamic Rewards Unleashed

Following weeks of preparation and hard work, we’re incredibly excited to open the Paribus Mainnet v1 tomorrow. This marks the welcome return of our protocol and heralds the beginning of our rewards program. For those who participated in our staking program, the concept behind the rewards program will be simple to understand. We’ve allocated 100 million PBX tokens to be issued as rewards to borrowers on the platform. This concept is even more exciting because the rewards are scheduled to be released evenly across every block and are anticipated to